Overview

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Status:
Terminated

Trial end date:
2020-02-06

Target enrollment:

Participant gender:

Summary

Background: - There are no established treatments for people with certain advanced kidney cancers. These tumors often don't respond well to currently available treatments. Researchers believe that two drugs that treat other diseases metformin and vandetanib could help people with advanced kidney cancer. Objective: - To test the combination of metformin and vandetanib in people with advanced kidney cancer. Phase I of the study will determine a safe dose for the drugs. Phase II will test this dose in people with certain kidney cancers. Eligibility: - For Phase I, people 18 and over with advanced kidney cancer - For Phase II, people 18 and over with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC), succinate dehydrogenase renal cell carcinoma (SDH-RCC), or advanced papillary renal cell carcinoma not related to a hereditary syndrome Design: - The study will last many months. - Participants will be screened with medical history and physical exam. - Participants will take the study drugs by mouth every day. - Participants will measure and record their blood pressure every day. - Participants will have many tests: - Blood and urine tests - Magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET) scan, and other imaging tests: they will lie in machines that take pictures of their body. - Electrocardiogram (ECG): soft electrodes will be stuck to the skin. A machine will record the hearts signals. - Bone scan - Some participants may have a gynecology evaluation or photos of skin tumors taken. - Participants will have an optional tumor biopsy. - After they stop taking the drugs, participants may have medical history, physical exam, and blood tests. They will be contacted once a year by phone to find out how they are doing.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Metformin